Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01457118 | An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies | PHASE2 | COMPLETED | 27 | — | — | Oct 1, 2011 | Nov 1, 2017 | Jul 12, 2021 | 7 | United States, Belgium |
To provide access to NKTR-102 to subjects who previously received NKTR-102 in a clinical trial and were without signs of disease progression since receiving NKTR-102.
| Arm | Type | Description |
|---|---|---|
| NKTR-102 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| NKTR-102 145 mg/m2 | DRUG | A 90 minute IV infusion of 145 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle. |
| NKTR-102 120 mg/m2 | DRUG | A 90 minute IV infusion of 120 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle. |
| NKTR-102 95 mg/m2 | DRUG | A 90 minute IV infusion of 95 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle. |
| NKTR-102 50 mg/m2 | DRUG | A 90 minute IV infusion of 50 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle. |
Inclusion: 1. Received prior treatment with NKTR-102 2. Free of disease progression since receiving NKTR-102 3. Adequate bone marrow and organ function 4. Treatment with NKTR-102 in the extension study to begin within 8 weeks after receipt of their of last dose of NKTR-102 5. Agree to use adequate ...